NEOABLE CO., LTD.

NEOABLE is built upon the core principle of “Moving Technology for Care,”

offering a breakthrough alternative to conventional static medical products.

The company’s core devices

—NEOX (smart electric cushion), NEO-M (AI-powered mattress),

and NEOSONIX (vibration therapy device)

—utilize automated pressure redistribution and sensor-based response systems,

making them ideally suited for aging societies and rehabilitation-focused medical facilities.

The business model goes beyond traditional hardware sales.

It follows a phased pathway of clinical validation → insurance integration → institutional procurement, enabling a hybrid B2B+B2G model.

With proven compatibility for institutional markets such as Japan’s Kaigo insurance system, European hospital purchasing structures,

and public tenders in the Middle East, NEOABLE is positioned for scalable impact.

Strengths

- Proprietary “Moving-Tech” platform offering real-time, responsive pressure relief

- Certified (CE, ISO13485) and proven in regulated markets (e.g., Japan), Clear clinical differentiation from passive competitors (ROHO, JAY)

- Hybrid business model (B2B + B2G) adaptable to hospital, insurance, and government channels

- Strong early traction: 3.7M USD Japan contract, pilot tests in UAE & Saudi Arabia

Weaknesses

- Limited brand awareness in non-Asian markets (e.g., Europe, Middle East)

- Capital-intensive scaling model (AI/motorized products require more production resources)

- Product localization (language, regulatory, insurance systems) needed per region

Opportunities

- Global aging population fueling demand for ulcer prevention and elderly care solutions

- Rising public health investments in GCC countries and Southeast Asia

- Entry into insurance-backed systems (Kaigo, EU DRG, Middle East’s e-claims)

Threats

- Price-sensitive procurement markets may favor low-cost static competitors

- Market entry dependent on regulatory approvals and pilot outcomes

- Geopolitical instability or policy shifts in emerging regions (e.g., Middle East tender cycles), Risk of low-cost imitation in low-barrier regions